



Immediate Release

Revenues at Rs: 272 crores. EBITDA at Rs: 77 crores. PAT at Rs: 53 crores

Bangalore, July 18th, 2007

Biocon Limited today announced its financial performance for the three months ended June 30th, 2007.

PERFORMANCE HIGHLIGHTS

- Sales grew by 28% Operating profits by 40%. Profit after tax by 36% over the same period in the previous year
- All business segments delivered robust growth. Biopharma performed particularly strongly. Margins in services were restrained by currency appreciation
- Branded products for Nephrology, Oncology and Cardio-Diabetes performed strongly
- Biocon licenses G-CSF (Granulocyte-Colony Stimulating Factor) to a global biopharmaceutical company for North America and the European Union
- Biocon enters into exclusive agreement with Invitrogen to market Insulin to the global cell culture market
- Biocon's discovery led research programs in particular Oral Insulin (IN105) and Anti-CD6 monoclonal antibody (T1h) continued to make good progress. IN105 completed Phase IC Human Clinical "Proof of Concept" trials. T1h will commence Phase II Human Clinical trials during Q2 FY08
- Biocon received regulatory approval from DCGI for bio-similar Streptokinase and GCSF
- Clinigene moved its operations to a new, state of the art, dedicated facility
- Syngene commenced construction of the dedicated facility for Bristol Myers Squibb

Outlook Commenting on the results, **Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon Limited**, said:

"I am pleased that we have delivered robust and growing profits at a time when we are challenged with increased R&D investments, strengthening currency and rising operating costs. This has been possible due to expanded markets for our bio-therapeutics as well as significant licensing income from our R&D programs. We see licensing as a strong affirmation of our innovation led business strategy and expect to realize even greater licensing revenues in the future.

The year ahead will be exciting but demanding. Whilst we will address the challenges posed by a depreciating dollar as well as increased operating costs through a series of measures that improve operating efficiency, we remain optimistic about the future thanks to our business verticals that are balanced between products and services.”

CORPORATE DEVELOPMENTS

Biocon enters into an exclusive licensing agreement for G-CSF.

Biocon entered into an exclusive licensing agreement with a global biopharmaceutical company to develop and market a bio-similar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union. Under the terms of the agreement, Biocon will receive an upfront licensing fee and following approval in the licensed territories, royalties from sales.

Biocon signs an exclusive agreement with INVITROGEN CORPORATION to market Insulin for cell culture

Biocon has signed an exclusive agreement with Invitrogen Corporation, a provider of essential life science technologies for disease research and drug discovery, to market pharmaceutical-grade insulin to the global cell culture market. The cell culture market is a large opportunity for Biocon’s Insulin.

Biocon files IMPD for IN 105 to conduct Phase I Clinical Trials in Europe.

Biocon has filed an Investigational Medical Product Dossier (IMPD) for IN105 to conduct a Phase I Clinical Trial in Sweden. The trial will be conducted at Karolinska University Hospital., Stockholm. This marks the first step in the international development plan for IN105.

Note: The discussions in this release reflect the audited financial performance of Biocon Limited based on Indian GAAP on a consolidated basis. This considers the financial performance of Biocon Limited, its wholly owned subsidiaries Syngene International Limited and Clinigene International Limited and its 51% joint venture Biocon Biopharmaceuticals Private Limited.

About Biocon

Established in 1978, Biocon Limited is one of India’s premier biotechnology companies. Biocon, its two wholly owned subsidiary companies, Syngene International Ltd and Clinigene International Ltd and its Joint Venture Company Biocon Biopharmaceuticals Pvt Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research, clinical research and enzymes. With successful initiatives in clinical development, bioprocessing and global marketing, Biocon delivers products and solutions to partners and customers across the globe. Visit us at www.biocon.com

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our

expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, nor our directors, or any of our affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Encl: Summarised Consolidated Profit & Loss Statement

For further information contact:

Paula Sengupta /Ravi Chander

Biocon Limited

Tel: +91 80 2808 2222

Fax: +91 80 2852 2226

Email: paula.sengupta@biocon.com

gayatri.appaya@biocon.com

FACT SHEET

BIOCON LIMITED (CONSOLIDATED)

PROFIT & LOSS STATEMENT (Rs. crores)

Particulars	Q1 FY 2008	Q1 FY 2007	Variance	Full Year
			Q1 FY 08 vs Q1 FY 07	ended March 31, 2007
INCOME Biopharmaceuticals Enzymes Contract research	206 21 44	161 22 29	28%-3%52%	755 95 136
			28%	
Total Sales Other income	271 1	212 1		986 4
Total Income / Revenues	272	213	28%	990
EXPENDITURE Material & Power Costs Staff costs Other expenses	130 30 35	119 18 21	9%65%68%	513 91 99
Manufacturing, staff & other exps	195	158	23%	702
			40%	
PBDIT /EBIDTA Interest and finance charges	77 3	55 2		288 10
			39%	
PBDT Depreciation	74 21	53 11		278 67
			24%	
PBT Taxes	53 1	42 4		211 17
			34%	
PROFIT FOR THE PERIOD Add/(less): Minority interest	52 1	38 1		194 6
			36%	
PAT	53	39		200
			36%	
EPS on issued capital (Rs)	5.3	3.9		20.0

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		<i>(Rs. crores)</i>
Particulars	As at 30-Jun-07	As at 31-Mar-07
SOURCES OF FUNDS Share Capital Reserves & Surplus	50 1,074	50 1,019
Total Shareholder's Funds	1,124	1,069
Minority interest	-2	-1
Deferred Tax Liability	45	45
Secured Loans Unsecured Loans	35 115	74 113
Total Loan Funds	150	187
Total APPLICATION OF FUNDS Fixed Assets (Net)	1,317 927	1,300 915
Intangible Assets Investments	51 99	51 79
Inventories Sundry debtors Cash and bank balances Loans and advances	177 282 6 58	161 307 9 53
Total Current Assets, Loans & Advances	523	530
Less: Current liabilities and provisions	283	275
Net Current assets	240	255
Total	1,317	1,300

18/07/2007

BIOCON LIMITED (CONSOLIDATED)		
STATEMENT OF CASH FLOWS		(Rs. crores)
Particulars	Full Year ended June 30, 2007	Full Year ended March 31, 2007
I. Cash Flow from Operating Activities Net profit before tax Less/Add: non-cash items/ items required separately Depreciation Others Changes in working capital and other provisions Cash generated from operations Tax paid (net of refunds) Net Cash provided by operating activities II. Cash Flow from Investing Activities Fixed Assets Change in minority Interest / dividend received Investments Net cash used for investing activities III. Cash Flows from Financing Activities Borrowings and other financing activities Net Cash provided/ (used) for financing activities IV. Net Change in Cash and Cash Equivalents (I+II+III) V. Cash & Cash Eq. at the beginning of the year VI CASH AND CASH EQUIVALENTS OF THE ESOP TRUST ACQUIRED DURING THE YEAR VII. Cash and Cash Eq. at the end of the year (IV+V+VI)	53 22 5 71	211 67 16 (128)
	150	165
	8	(13)
	158	152
	(44) -2 (47)	(190) 2 2 (13)
	(89)	(199)
	(75)	51
	(75)	51
	(6)	4
	9 3	2 3
	6	9